Comparative decreases in tyrosinase, TRP-1, TRP-2, and Pmel 17/silver antigenic proteins from melanotic to amelanotic stages of syngeneic mouse cutaneous melanomas and metastases

Cancer Research

Volumn 58, Issue 7, 1998, Pages 1521-1523

  Orlow, Seth J ^a   Silvers, Willys K ^b,c   Zhou, Bao Kang ^a   Mintz, Beatrice ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANIN; MONOPHENOL MONOOXYGENASE; SILVER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER STAGING; DIAGNOSTIC VALUE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN METASTASIS;

ANIMALS; ANTIGENS, NEOPLASM; DISEASE PROGRESSION; IMMUNOBLOTTING; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA; MELANOMA, AMELANOTIC; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MONOPHENOL MONOOXYGENASE; NEOPLASM STAGING; OXIDOREDUCTASES; PROTEINS; SKIN NEOPLASMS;

EID: 0032054235     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Birchard, V., Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Culie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
2. Wölfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Büschenfelde, K-H., and Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24: 759-764, 1994.
3. Robbins, P. F., El-Gamil, M., Kawakami, Y., and Rosenberg, S. A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res., 54: 3124-3126, 1994.
4. Spagnoli, G. C., Schaefer, C., Willimann, T. E., Kocher, T., Amoroso, A., Juretic, A., Zuber, M., Luscher, U., Harder, F., and Heberer, M. Peptide-specific CTL in tumor-infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int. J. Cancer, 64: 309-315, 1995.
5. Wang, R-F., Robbins, P. F., Kawakami, Y., Kang, X-Q., and Rosenberg, S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., 181: 799-804, 1995.
6. Wang, R-F., Appella, E., Kawakami, Y., Kang, X., and Rosenberg, S. A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med., 184: 2207-2216, 1996.
7. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716-719, 1994.
8. Bakker, A. B. H., Schreurs, M. W. J., Tafazzul, G., De Boer, A. J., Kawakami, Y., Adema, G. J., and Figdor, C. G. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer, 62: 97-102, 1995.
9. Zarour, H., De Smet, C., Lehmann, F., Marchand, M., Lethé, B., Romero, P., Boon, T., and Renauld, J-C. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J. Invest. Dermatol., 107: 63-67, 1996.
10. Rivoltini, L., Loftus, D. J., Barracchini, K., Arienti, F., Mazzocchi, A., Biddison, W. E., Salgaller, M. L., Appella, E., Parmiani, G., and Marincola, F. M. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J. Immunol., 156: 3882-3891, 1996.
11. Chen, Y-T., Stocken, E., Tsang, S., Coplan, K. A., and Old, L. J. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. Natl. Acad. Sci. USA, 92: 8125-8129, 1995.
12. Sarantou, T., Chi, D. D. J., Garrison, D. A., Conrad, A. J., Schmid, P., Morton, D. L., and Hoon, D. S. B. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res., 57: 1371-1376, 1997.
13. de Vries, T. J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D. J., and van Muijen, G. N. P. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res., 57: 3223-3229, 1997.
14. Marincola, F. M., Hijazi, Y. M., Fetsch, P., Salgaller, M. L., Rivoltini, L., Cormier, J., Simonis, T. B., Duray, P. H., Herlyn, M., Kawakami, Y., and Rosenberg, S. A. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother., 19: 192-205, 1996.
15. Wagner, S. N., Wagner, C., Schultewolter, T., and Goos, M. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Cancer Immunol. Immunother., 44: 239-247, 1997.
16. Bradl, M., Klein-Szanto, A., Porter, S., and Mintz, B. Malignant melanoma in transgenic mice. Proc. Natl. Acad. Sci. USA, 88: 164-168, 1991.
17. Mintz, B., and Silvers, W. K. Transgenic mouse model of malignant skin melanoma. Proc. Natl. Acad. Sci. USA, 90: 8817-8821, 1993.
18. Le Fur, N., Kelsall, S. R., Silvers, W. K., and Mintz, B. Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy. Proc. Natl. Acad. Sci. USA, 94: 5332-5337, 1997.
19. 2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models. Proc. Natl. Acad. Sci. USA, 94: 7561-7565, 1997.
20. Orlow, S. J., Hearing, V. J., Sakai, C., Urabe, K., Zhou, B.-K., Silvers, W. K., and Mintz, B. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc. Natl. Acad. Sci. USA, 92: 10152-10156, 1995.
21. Orlow, S. J., Boissy, R. E., Moran, D. J., and Pifko-Hirst, S. Subcellular distribution of tyrosinase and tyrosinase-related protein-1: implications for melanosomal biogenesis. J. Invest. Dermatol., 100: 55-64, 1993.
22. Jimenez, M., Tsukamoto, K., and Hearing, V. J. Tyrosinases from two different loci are expressed by normal and by transformed melanocytes. J. Biol. Chem., 266: 1147-1156, 1991.
23. Tsukamoto, K., Jackson, I. J., Urabe, K., Montague, P. M., and Hearing, V. J. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPA-chrome tautomerase. EMBO J., 11: 519-526, 1992.
24. Kobayashi, T., Urabe, K., Orlow, S. J., Higashi, K., Imokawa, G., Kwon, B. S., Potterf, B., and Hearing, V. J. The Pmel17/silver locus protein. Characterization and investigation of its melanogenic function. J. Biol. Chem., 269: 29198-29205, 1994.
25. McGovern, V. J. Melanoma. Histological Diagnosis and Prognosis. New York: Raven Press, 1983.
26. Steel, K. P., Davidson, D. R., and Jackson, I. J. TRP-2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor. Development (Camb.), 115: 1111-1119, 1992.
27. Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., El-Gamil, M., Rosenberg, S. A., and Yang, J. C. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med., 185: 453-459, 1997.